기업 CEO 초청 특별강연

June 26 (Friday), 2020 11:00-11:30

Innovative R&D based on the hidden Assets

We stand on the world of a technology revolution that will fundamentally alter the way we live, work, and relate to one another. All of us are responsible for adapting its evolution, and we should hold the opportunity and responsibility and have to direct it toward a future that reflects our objectives and added values. In CJ CheilJedang, we bring delicious indulgences to the table, lead the future of biotechnology and help the world grow together by innovative R&Ds such as differentiated food processing, human and animal nutrition and microbiome therapeutics.

For this talk, a few cases of innovative R&Ds from global companies will be discussed. In addition, a brief story of innovative R&D in CJ CheilJedang based on the hidden Assents from the current capabilities will also be a topic for the talk.
Executive Vice President Yunil Hwang CV
CJ Cheiljedang, Corp., Korea
June 26 (Friday), 2020 11:30-12:00

Development of innovative immune-therapeutics based on two core technologies of Genexine

While cancer is among the leading causes of death worldwide, the cancer treatment is improving, saving lives and extending survival for many people, driven by rapidly evolving advances in immunotherapy. Immunotherapy marks an entirely different way of treating cancer by targeting the immune system, not the tumor itself, resulting in a significant change of the treatment paradigm in many of the cancer types.Genexine is an innovative biotechnology company focused on developing Immuno-therapeutics by utilizing two proprietary core technologies for therapeutic vaccines and immunofusion proteins - DNA therapeutic vaccine and hyFc® based long-acting fusion protein technology. Among the pipelines, GX-I7, a long-acting interleukin-7 that increases T-cell counts to be used as a treatment for lymphopenia and cancer, and GX-188E, a DNA therapeutic vaccine targeting cervical cancer associated with human papilloma virus (HPV) type 16 and 18 are to be introduced in this talk. GX-I7 is currently under clinical trial development in various cancer treatment. GX-188E is also under the phase 2 clinical study with a combination therapy of pembrolizumab in patients with HPV 16- and 18- positive advanced cervical cancer who failed the first or later line of therapy.
President Hyi-Jeong Ji CV
Genexine, Ltd., Korea
loading